Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.0941
Handel nachbörslich:
.09
0.09
+
Palatin Technologies Inc. Aktie (PTN) Neueste Nachrichten
Palatin reveals potential diabetic retinopathy treatments - Investing.com
Palatin Unveils Promising Preclinical Data For Diabetic Retinopathy Treatments At ARVO 2025 - Nasdaq
Palatin reveals potential diabetic retinopathy treatments By Investing.com - Investing.com South Africa
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - GuruFocus
Palatin expects $11.5M financing to cure NYSE American delisting notice - MSN
Palatin Technologies Announces Closing of Reduced Public Offering | PTN Stock News - GuruFocus
Palatin Technologies Announces Closing of Reduced Public Offering - Stock Titan
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 - The Malaysian Reserve
Palatin Technologies (PTN) Reveals Promising Phase 3 Study Results for PL9643 in Dry Eye Disease | PTN Stock News - GuruFocus
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 | PTN Stock News - GuruFocus
PTN Faces Delisting from NYSE American, Shares Transition to OTC Market | PTN Stock News - GuruFocus
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice - Lelezard
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice | PTN Stock News - GuruFocus
Palatin Technologies faces delisting from NYSE American due to low stock price - Investing.com
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs By Investing.com - Investing.com South Africa
Palatin Prices $11.5 Mln Public Offering - Nasdaq
Palatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug Development - Nasdaq
Palatin Technologies Stock Trading Halted Pending Material Announcement - marketscreener.com
Palatin Technologies Announces Pricing Of Up To $23 Million Public Offering - marketscreener.com
Palatin (PTN) Aims to Address Delisting Concerns with Public Offering | PTN Stock News - GuruFocus
Palatin secures $11.5 million to tackle NYSE delisting, boost obesity drugs - Investing.com Canada
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice | PTN Stock News - GuruFocus
Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice - StreetInsider
Palatin Technologies Announces Pricing of up to $23 Million Public Offering - StreetInsider
Palatin Technologies Announces Pricing of up to $23 Million Public Offering | PTN Stock News - GuruFocus
Palatin Technologies sets terms for $23 million offering - Investing.com
Palatin (PTN) Unveils Promising Data for Glaucoma Treatment Cand - GuruFocus
Palatin Presents Promising Preclinical Data for Melanocortin Ago - GuruFocus
Palatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma Treatment - Nasdaq
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy - GuruFocus
Palatin (PTN) Unveils Promising Data for Glaucoma Treatment Candidate PL9588 | PTN Stock News - GuruFocus
Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy – Company AnnouncementFT.com - Financial Times
Palatin Technologies (NYSE:PTN) Coverage Initiated at StockNews.com - Defense World
After The Stock Rose 2.56% Over The Week, Is Palatin Technologies Inc (AMEX: PTN) Still A Buy? - Marketing Sentinel
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease - The Malaysian Reserve
Palatin Announces Breakthrough Symptom Resolution in Updated Ana - GuruFocus
Palatin (PTN) Announces Promising Results for PL9643 in Dry Eye Disease Study | PTN Stock News - GuruFocus
Palatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DED - Nasdaq
First-Ever Complete Symptom Resolution: Game-Changing Phase 3 Results in $6B Dry Eye Market - Stock Titan
Market Resilience: Palatin Technologies Inc (PTN) Finishes Weak at 0.66, Down -5.41 - DWinneX
The Attractiveness of Investing In Palatin Technologies Inc (PTN) is Growing - knoxdaily.com
Trading Day Triumph: Palatin Technologies Inc (PTN) Ends at 0.21, a -1.24 Surge/Plunge - DWinneX
Investor Network: Palatin Technologies, Inc. to Host Earnings Call - ACCESS Newswire
Palatin Technologies (NYSE:PTN) Now Covered by StockNews.com - Defense World
NYSE to Commence Delisting Proceedings Against Solo Brands, Inc. (DTC) - Business Wire
A Guide To The Risks Of Investing In Palatin Technologies Inc (PTN) - knoxdaily.com
Palatin Technologies Inc’s Banking’s 100-Day Moving Average at 0.8728: Will the Stock Break Through? - investchronicle.com
StockNews.com Begins Coverage on Palatin Technologies (NYSE:PTN) - Defense World
Palatin’s obesity study shows promise in appetite control By Investing.com - Investing.com Canada
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - The Malaysian Reserve
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin (PTN) Reports Positive Phase 2 Study Results for Obesity Treatment | PTN Stock News - GuruFocus
Palatin’s obesity study shows promise in appetite control - Investing.com Australia
Palatin Reports Positive Appetite Suppression Results From Phase - GuruFocus
Breakthrough Obesity Treatment Shows 71% Appetite Control, Blocks Post-Treatment Weight Rebound - Stock Titan
0.84%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):